Related references
Note: Only part of the references are listed.Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1 Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis
Zhenling Yao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Brian G. Feagan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
Gerard Bruin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan et al.
LANCET (2017)
Current and emerging therapeutic targets for IBD
Markus F. Neurath
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
George E. Fragoulis et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials
Lei Diao et al.
CLINICAL PHARMACOKINETICS (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
M. Rosario et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
Dhavalkumar D. Patel et al.
IMMUNITY (2015)
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody
Sanjaya Singh et al.
MABS (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics
Juan Jose Perez Ruixo et al.
AAPS JOURNAL (2013)
Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity
Z.H. Xu et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
A.A. Fasanmade et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis
Yaowei Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
The roles of IL-17A in inflammatory immune responses and host defense against pathogens
Yoichiro Iwakura et al.
IMMUNOLOGICAL REVIEWS (2008)
Polymorphisms in the IL-12β and IL-23R genes are associated with psoriasis of early onset in a UK cohort
Rhodri Ll. Smith et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
The IL23 axis plays a key role in the pathogenesis of IBD
Dermot McGovern et al.
GUT (2007)
PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2005)